LeMaitre Vascular Reports Strong Q2 2025 Financial Results
BURLINGTON, Mass. — LeMaitre Vascular, Inc. (Nasdaq: LMAT), a prominent provider of innovative vascular devices, has released its financial results for the second quarter of 2025. The company is excited to announce a quarterly dividend of $0.20 per share alongside a positive outlook for the future.
Q2 2025 Financial Highlights
In Q2 2025, LeMaitre Vascular achieved remarkable sales totaling $64.2 million, marking a significant growth of 15%, which was also reflected in organic growth figures. Other key highlights from the quarter include:
- Gross margin rose to 70.0%, an increase of 110 basis points.
- Operating income reached $16.1 million, reflecting a 12% increase from the previous year.
- Operating margin stood effectively at 25%.
- Net earnings per diluted share increased to $0.60, an increase of 16%.
- The cash balance grew by $16.9 million sequentially, totaling $319.5 million.
The notable growth in sales was propelled by robust demand for catheters, which saw a 27% increase, and grafts that exceeded previous benchmarks with a 19% increase in sales. The company also reported regional sales growth with the EMEA region up by 23%, while both the Americas and APAC regions experienced 12% growth. Notably, price adjustments contributed 8% to the sales growth, complemented by a 7% increase in volume.
Driving Factors Behind Growth
The company's improved gross margin this quarter can be attributed to higher average selling prices and efficient manufacturing processes. The increase in operating income signals a successful strategy in managing costs alongside increasing sales. LeMaitre’s Chairman and CEO, George LeMaitre, expressed optimism regarding the company's trajectory, stating, “2025 is looking as though it will be another productive year for both sales and profit, and we are excited about Artegraft’s launch outside the U.S., which is ahead of schedule.”
Looking Ahead: Business Outlook
As LeMaitre Vascular advances into Q3 2025, the company is adjusting its guidance based on Q2’s performance. Here are the projections:
Q3 2025 Guidance
Sales are expected to range between $61.2 million and $63.2 million, with a midpoint forecast of $62.2 million, reflecting a growth of 13% year-over-year and 15% in organic growth.
Full Year Guidance
For the full year, LeMaitre anticipates sales between $248 million and $254 million, projected midpoint at $251 million, indicating a 14% increase year-over-year and 15% in organic terms.
Quarterly Dividend Announcement
In an effort to reward loyal stockholders, on July 30, 2025, the Board of Directors approved the payment of a $0.20 dividend per share of common stock. This dividend is set to be distributed on September 4, 2025, to those on record as of August 21, 2025.
Share Repurchase Program
On February 18, 2025, the Board authorized a repurchase of up to $75 million of its common stock. This program is subject to suspension or discontinuation at any point and is scheduled to conclude on February 17, 2026, unless extended.
Upcoming Conference Call
Investors should note that management will host a conference call at 5:00 PM ET today. The call will be accessible via the company’s website, and interested parties can register online to receive dial-in information to join the conversation.
About LeMaitre Vascular, Inc.
LeMaitre Vascular is at the forefront of developing, manufacturing, and marketing innovative devices and implants dedicated to treating peripheral vascular disease, which affects millions globally. With a focus on meeting the demands of vascular surgeons, LeMaitre continues to lead in creating groundbreaking solutions.
Frequently Asked Questions
What are the key results from LeMaitre Vascular’s Q2 2025 report?
LeMaitre Vascular reported sales of $64.2 million, a gross margin of 70.0%, and earnings per diluted share of $0.60.
What drove the sales growth in Q2 2025?
Sales growth was driven by increased demand for catheters and grafts and higher average selling prices.
What is the company's dividend plan for 2025?
The company has approved a quarterly dividend of $0.20 per share, scheduled for payment on September 4, 2025.
What guidance has LeMaitre provided for Q3 2025?
The company projects sales in Q3 2025 between $61.2 million and $63.2 million.
What initiatives is LeMaitre launching for the future?
LeMaitre is focusing on expanding its product lines, including the launch of Artegraft and an ongoing share repurchase program.
